Skip to main content
. Author manuscript; available in PMC: 2022 Oct 1.
Published in final edited form as: J Subst Abuse Treat. 2021 Mar 27;129:108372. doi: 10.1016/j.jsat.2021.108372

Table 2.

Naloxone-related experiences and beliefs among rural and small metro area pharmacists registered with NYS opioid overdose prevention program (n=60), stratified by naloxone dispensation, 2019.

Measures Distribution, n (%)
All Naloxone dispensed (any vs. none) p-value
Total 60 (100.0) 35 (58.33)
Support sale of naloxone in pharmacy 0.162
  Yes 56 (93.3) 34 (60.7)
  No 4 (6.7) 1 (25.0)
Believe pharmacist should play bigger role in OD prevention 0.608
  Yes 52 (86.7) 31 (59.6)
  No 8 (13.3) 4 (50.0)
Do you think that selling naloxone to PWUO: 0.594
 Makes opioid use increase?
  Yes 17 (28.3) 9 (52.9)
  No 43 (71.7) 26 (60.5)
 Sends a message that opioid use is ok? 0.593
  Yes 24 (40.0) 13 (54.2)
  No 36 (60.0) 22 (61.1)
 Reduces the risk of opioid overdoses? 0.089
  Yes 53 (88.3) 33 (62.3)
  No 7 (11.7) 2 (28.6)
Since registering for OOPP, pharmacist experienced:
 Loss of business 0.854
  Yes 9 (15.0) 5 (55.6)
  No 51 (85.0) 30 (58.8)
 Theft/crime potentially committed by naloxone customers 0.513
  Yes 12 (20.0) 8 (66.7)
  No 48 (80.0) 27 (56.2)
 Increase in number of prescriptions filled 0.337
  Yes 21 (35.0) 14 (66.7)
  No 39 (65.0) 21 (53.8)